Azathioprine + Ustekinumab Srlf Interaction
Moderateinteraction on record
Description
Immunomodulator used concomitantly in approximately 30% of Crohn's disease and ulcerative colitis subjects; did not appear to influence overall safety or efficacy.
Source: NLP:ustekinumab-srlf